- €13.00bn
- €12.43bn
- €3.93bn
Barclays cautious on European pharma in H1, sees re-rating chance in H2
RBC names specialty pharma and biotech launches to watch in 2025
Top of the Street: European reinsurers, Schindler, Moncler, E.ON, Ipsen
BofA cuts Ipsen citing valuation, shares slip
Brief: Ipsen, Biomunex Announce Exclusive Global Licensing Agreement For BMX-502
Brief: Ipsen Ups FY Guidance, Posts Q3 Revenue Of EUR 836.6 Mln
US FDA declines to approve Camurus' rare hormone disorder drug
Brief: UK's MHRA Says Elafibranor Approved As First Medicine To Treat Adults With A Rare Liver Disease Known As Primary Biliary Cholangitis
Brief: Ipsen’s Iqirvo Receives European Approval
Live Markets: Cenbank divergences ending, apart from Japan - Amundi
Live Markets: R&D picks in Europe
Ipsen rises after RBC ups on Iqirvo U.S. approval
Brief: Ipsen Provides Update On Contact-02 Phase III Trial
Employee of French drugmaker Ipsen to plead guilty to US insider trading (updated)
Employee of French drugmaker Ipsen to plead guilty to US insider trading
Brief: Ipsen Receives CHMP Positive Opinions For Iqirvo And Kayfanda
Brief: EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab)
Ipsen drops on H1 results, as guidance hike already anticipated
Brief: Ipsen And Day One Enter Into Exclusive Ex-U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor